StockData
Aldeyra Therapeutics, Inc. logo

Aldeyra Therapeutics, Inc. (ALDX) stock

ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.69+0.02 (+3.63%)

Close on Nov 17, 2026Market cap $41.86MP/E –Yield –

Aldeyra Therapeutics total assets

Total assets on the balance sheet at the end of each period.

Aldeyra Therapeutics's total assets was $47.54M at Jun 30, 2026. For fiscal 2025 it was $72.06M, down 31.1% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $233.14M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$72.06M-31.1%
FY2024Dec 31, 2024$104.61M-29.5%
FY2023Dec 31, 2023$148.33M-18.2%
FY2022Dec 31, 2022$181.29M-22.2%
FY2021Dec 31, 2021$233.14M+179.7%
FY2020Dec 31, 2020$83.35M+10.4%
FY2019Dec 31, 2019$75.52M-20.6%
FY2018Dec 31, 2018$95.09M+115.3%
FY2017Dec 31, 2017$44.17M+75.4%
FY2016Dec 31, 2016$25.19M-10.7%
FY2015Dec 31, 2015$28.20M+221.0%
FY2014Dec 31, 2014$8.79M+134.7%
FY2013Dec 31, 2013$3.74M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$47.54M-44.0%
Q1 FY2026Mar 31, 2026$66.48M-28.7%
Q4 FY2025Dec 31, 2025$72.06M-31.1%
Q3 FY2025Sep 30, 2025$77.80M-33.7%
Q2 FY2025Jun 30, 2025$84.96M-32.6%
Q1 FY2025Mar 31, 2025$93.20M-34.0%
Q4 FY2024Dec 31, 2024$104.61M-29.5%
Q3 FY2024Sep 30, 2024$117.32M-20.3%
Q2 FY2024Jun 30, 2024$126.04M-19.0%
Q1 FY2024Mar 31, 2024$141.30M-16.0%
Q4 FY2023Dec 31, 2023$148.33M-18.2%
Q3 FY2023Sep 30, 2023$147.28M-22.4%
Q2 FY2023Jun 30, 2023$155.62M-22.6%
Q1 FY2023Mar 31, 2023$168.22M-24.5%
Q4 FY2022Dec 31, 2022$181.29M-22.2%
Q3 FY2022Sep 30, 2022$189.69M-23.3%
Q2 FY2022Jun 30, 2022$201.02M-21.6%
Q1 FY2022Mar 31, 2022$222.69M+51.2%
Q4 FY2021Dec 31, 2021$233.14M+179.7%
Q3 FY2021Sep 30, 2021$247.22M+179.9%
Q2 FY2021Jun 30, 2021$256.43M+258.0%
Q1 FY2021Mar 31, 2021$147.31M+133.7%
Q4 FY2020Dec 31, 2020$83.35M+10.4%
Q3 FY2020Sep 30, 2020$88.32M+14.1%
Q2 FY2020Jun 30, 2020$71.63M-3.0%
Q1 FY2020Mar 31, 2020$63.03M-28.5%
Q4 FY2019Dec 31, 2019$75.52M-20.6%
Q3 FY2019Sep 30, 2019$77.44M+108.6%
Q2 FY2019Jun 30, 2019$73.84M+70.6%
Q1 FY2019Mar 31, 2019$88.13M+99.5%
Q4 FY2018Dec 31, 2018$95.09M+93.2%
Q3 FY2018Sep 30, 2018$37.13M+40.3%
Q2 FY2018Jun 30, 2018$43.29M+37.3%
Q4 FY2017Dec 31, 2017$44.17M+75.4%
Q3 FY2017Sep 30, 2017$49.23M+68.6%
Q2 FY2017Jun 30, 2017$26.47M-19.5%
Q1 FY2017Mar 31, 2017$31.53M–
Q4 FY2016Dec 31, 2016$25.19M–
Q3 FY2016Sep 30, 2016$29.19M–
Q2 FY2016Jun 30, 2016$32.88M–

More Aldeyra Therapeutics figures

See a number that looks wrong?